Arrowhead Pharmaceuticals (ARWR) Income from Non-Controlling Interests (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Income from Non-Controlling Interests of -$4.8 million for Q1 2026, down 3415.07% on a QoQ basis from $146000.0 in Q4 2025, and down 87.45% year-over-year from -$38.6 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 87.45% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 547.05% YoY) and the FY2025 annual result came in at $2.1 million, down 43.71% from the prior year.
- Income from Non-Controlling Interests was -$4.8 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $146000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $10.3 million in Q3 2025 and bottomed at -$4.8 million in Q1 2026.
- A 5-year average of $350214.3 and a median of -$77000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 631.69% in 2025, while the deepest fall reached 1295.37% in 2025.
- Arrowhead Pharmaceuticals' Income from Non-Controlling Interests stood at -$486000.0 in 2022, then soared by 492.8% to $1.9 million in 2023, then slumped by 126.56% to -$507000.0 in 2024, then soared by 128.8% to $146000.0 in 2025, then sank by 3415.07% to -$4.8 million in 2026.
- Business Quant data shows ARWR's Income from Non-Controlling Interests at -$4.8 million in Q1 2026, $146000.0 in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Arrowhead Pharmaceuticals | 12.14 Bn | 10.36 Bn | - | -4.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.84 Mn |
| Dec 31, 2025 | 146,000.00 |
| Sep 30, 2025 | 10.25 Mn |
| Jun 30, 2025 | 876,000.00 |
| Mar 31, 2025 | -2.58 Mn |
| Dec 31, 2024 | -507,000.00 |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 249,000.00 |
| Mar 31, 2024 | 216,000.00 |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | -300,000.00 |
| Mar 31, 2023 | -999,000.00 |
| Dec 31, 2022 | -486,000.00 |
| Sep 30, 2022 | -431,000.00 |
| Sep 30, 2014 | 6.05 Mn |
| Jun 30, 2014 | 2,468.00 |
| Mar 31, 2014 | -40,179.00 |
| Dec 31, 2013 | -57,420.00 |
| Sep 30, 2013 | 2.05 Mn |
| Jun 30, 2013 | -98,618.00 |